Several econometric studies have concluded that technical progress embodied in equipment is a major source of manufacturing productivity growth. Other research has suggested that, over the long run, growth in the U.S. economy's "health output" has been at least as large as the growth in non-health goods and services. One important input in the production of health-pharmaceuticals-is even more R&D-intensive than equipment.
In his seminal 1956 paper, Robert Solow showed that, for sustained economic growth to occur, technological progress is necessary:
In that paper, Solow assumed that technical progress was exogenous: it descends upon the economy like "manna from heaven," automatically and regardless of whatever else is going on in the economy (Jones (1998, 32-3) ).
More recent theoretical ("endogenous growth") models (Romer (1990) ) relaxed this assumption: they have hypothesized that "technical progress is driven by research and development" ((Jones (1998, 89-90) ):
Empirical evidence (e.g. Griliches and Lichtenberg (1984) , Lichtenberg and Siegel (199?) ) is consistent with the hypothesis that firms and industries that perform more R&D exhibit higher productivity growth.
Solow and other economists have recognized since the late 1950s that there are two kinds of technical progress: disembodied and embodied.
Suppose that agent i in the economy (e.g. a firm or government agency) engages in research and development. If technical progress is disembodied, another agent (j) can benefit from agent i's R&D whether or not he purchases agent i's products. But if technical progress is embodied, agent j benefits from agent i's R&D only if he purchases agent i's products. Solow conjectured that most technical progress was embodied. In one paper (Solow (1962, p. 76) ), he assumed that "all technological progress needs to be 'embodied' in newly produced capital goods before there can be any effect on output."
A number of econometric studies have investigated the hypothesis that capital equipment employed by U.S. manufacturing firms embodies technological change, i.e.
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Economic growth that "each successive vintage of investment is more productive than the last." Equipment is expected to embody significant technical progress due to the relatively high R&D-intensity of equipment manufacturers. According to the National Science Foundation, the R&D-intensity of machinery and equipment manufacturing is about 50% higher than the R&D-intensity of manufacturing in general, and 78% higher than the R&D intensity of all industries.
One method that has been used to test the equipment-embodied technical change hypothesis is to estimate manufacturing production functions, including (mean) vintage of equipment as well as quantities of capital and labor. Bahk and Gort (1993) argued that "we can take due account of the effect of vintage by measuring the average vintage of the stock" (p. 565). Similarly, Sakellaris and Wilson (2000) stated that "a standard production function estimation (in logs) provides an estimate of embodied technical change by dividing the coefficient on average age [of equipment] by the coefficient on capital stock" (capital's share in total cost).
These studies have concluded that technical progress embodied in equipment is a major source of manufacturing productivity growth. Hulten (1992) found that as much as 20 percent (and perhaps more) of the BLS total-factor-productivity change (in manufacturing) can be directly associated with embodiment-the higher productivity of new capital than old capital. For equipment used in U.S. manufacturing, best-practice technology may be as much as 23 percent above the average level of technical efficiency. Bahk and Gort (1993) concluded that "Industrywide learning appears to be uniquely related to embodied technical change of physical capital. Once due account is taken of the latter variable, residual industrywide learning [disembodied technical change] disappears as a significant explanatory variable" (p. 579). And Sakellaris and Wilson (2000) estimate that "each vintage is about 12 percent more productive than the previous year's vintage (in the preferred specification)", and that equipment-embodied technical change accounted for about two thirds of U.S. manufacturing productivity growth between 1972 and 1996.
Although equipment-embodied technical progress has contributed to U.S.
economic growth, it has probably had an undesirable side effect: increasing economic inequality. 1 Bartel and Lichtenberg (1987) presented evidence that reductions in the mean age of equipment reduce the relative demand for, and wages of, less-educated workers. Support for the "skill-biased technical change" hypothesis has been provided by numerous other studies.
Although virtually all previous empirical studies of embodied technical progress have focused on equipme nt used in manufacturing, embodied technical progress may also be an important source of economic growth in another sector of the economy: health care.
Recent research has suggested that, over the long run, growth in the U.S. economy's "health output" ha s been at least as large as the growth in non-health goods and services.
2 Between 1900 and 1997, life expectancy at birth increased from 49.2 years to 76.5 years Anderson (1999) ). Nordhaus (2002) estimated that, "to a first approximation, the economic value of increases in longevity over the twentieth century is about as large as the value of measured growth in non-health goods and services". Moreover, there is evidence that the quality as well as the length of life of life have increased. According to a new study, which looked at a sample of 19,000 Americans age 65 and older, the chances that elderly Americans will be devastated by chronic disabilities like stroke and dementia have declined sharply. The number of older people who become severely disabled has been declining gradually for more than a decade, but the decline became much sharper at the end of the 1990's.
3 1 According to a recent article, "For 30 years the gap between the richest Americans and everyone else has been growing so much that the level of inequality is higher than in any other industrialized nation….many economists [have] come to see inequality as a basic feature of the new high-tech economic scene." ("Grounded by an income gap," New York Times, Dec. 15, 2001 .) 2 Evidently, officials at the United Nations feel that per capita GDP growth is an incomplete measure of economic growth, broadly defined: they publish the "human development index," which is an (unweighted) average of three indexes: a life expectancy index, an education index, and an index of per capita GDP. 3 Scientists at the National Institute on Aging, which sponsored the study, said the decline probably resulted from a variety of factors, including more widespread knowledge of the benefits of diet and exercise, fewer people smoking, new drugs for heart problems and other illnesses, and advances in eye surgery. Advances in prescription drugs and medical technology have also contributed to the decline. "Decrease in Chronic Illness Bodes Well for Medicare Costs," New York Times, May 8, 2001 R&D Technical progress
Thus health output appears to be increasing at least as fast as conventional output.
Moreover, one important input in the production of health-pharmaceuticals-is even more R&D-intensive than equipment. According to the NSF, the R&D intensity of drugs and medicines manufacturing is 74% higher than the R&D intensity of machinery and equipment manufacturing (Figure 1 ). Therefore, it is quite plausible that there is also a high rate of pharmaceutical-embodied technical progress.
The objective of this paper is to test the pharmaceutical-embodied technical progress hypothesis-the hypothesis that newer drugs increase the length and quality of life-and to estimate the rate of progress. In one respect, the approach we take is similar to that used in previous studies of manufacturing: we estimate production functions that include vintage. But our methodology differs in a number of ways. We estimate health production functions, in which the dependent variables are various indicators of health status, such as presence of physical or cognitive limitations. We estimate these relationships using extremely disaggregated-prescription-level-cross-sectional data derived primarily from the 1997 Medical Expenditure Panel Survey. And we define vintage as the year in which the Food and Drug Administration (FDA) first approved a drug's active ingredient(s).
Theoretical Framework
The simplest model one might estimate to determine the effect of drug vintage on post-treatment health is
where:
H POST is a measure of a person's post-treatment health status V is the vintage (FDA approval year) of the drug(s) consumed by the person during a period Z are other potential determinants of H POST that may be correlated with V (e.g. medical condition, age, sex, and education) u is a disturbance For several reasons, however, the consistency and efficiency of estimates of this effect may be improved by extending eq. (1) to include pre-treatment health status:
H PRE is a measure of a person's pre-treatment health status, i.e. her status at the beginning of the period
We will estimate both models. Estimation of eq. (2) will reveal the effect of vintage on post-treatment health status, conditional on pre-treatment health status. 4 The first reason to control for H PRE is that many of the health indicators that we will ana lyze are fairly subjective: they are responses to questions such as "do you have difficulty walking?," or "do you suffer from cognitive limitations?". There may be significant differences in the way people whose "true" health is the same respond to such questions. But as long as these differences remain the same in the pre-and post-treatment health surveys, they won't affect our estimates.
The second reason is that H POST may depend on the vintage of drugs consumed in previous periods as well as the period of observation. Suppose that H POST = f(V, V -1 , V -2 ,…). If the coefficients on V decay geometrically with respect to time, one may express H POST as a linear function of current V and its own lagged value (H PRE ). Under these assumptions, b 1 may be interpreted as the short-run effect of V on health, and (b 1 / (1 -b 3 )) may be interpreted as the long-run effect.
The third reason to control for H PRE is that assignment of drugs to individuals is not random. Moreover, a simple but plausible theory of how drugs are assigned to people, which we sketch below, suggests that V may be (negatively) correlated with H PRE . If this is the case, estimates of eq.
(1) will yield estimates of the effect of drug vintage on post-treatment health that are biased downward 5 . 4 If age affects the rate of depreciation of health as well as the level of health (e.g., health declines more rapidly among the elderly), then age should reduce H POST , conditional on H PRE . 5 Another concern is the issue of access to drugs. Should this be restricted, we would expect people with access to newer drugs to have better outcomes, hence rendering the estimates from our proposed model to be potentially misleading. Although it remains unobserved, studies have shown wide variation in health care usage exists among apparently comparable populations living in neighboring communities. For details on small area analysis, refer for instance to Wennberg, John E. et al (1980) .
Suppose that a person's (post-treatment) utility function is:
Y is the person's gross income (assumed to be exogenous) p V (p V > 0) is the "price of vintage", i.e. the difference in price between a drug of vintage t+1 and a drug of vintage t. 6 Hence (Y -p V V) is the person's "residual income", i.e. income net of expenditure on drug vintage.
Further suppose that the (post-treatment) health production function is of the form
H PRE is a measure of a person's pre-treatment health status (also assumed to be exogenous).
Assume that the partial derivatives of H POST with respect to both V and H PRE are positive:
increases in pre-treatment health and in drug vintage both increase post-treatment health.
Eq. (1) can be regarded as a linear version of eq. (4), in which H PRE is included in the disturbance.
Substituting (4) into (3),
Using newer drugs (increasing V) affects utility in two opposite ways: it increases U by increasing H POST , but reduces utility by reducing residual income (Y -p V V). A utilitymaximizing consumer chooses V to balance these two effects.
We now make one further assumption about the health production function (4): a "nega tive interaction" between V and H PRE ((∂ 2 H POST / ∂ V ∂ H PRE ) < 0), i.e. we assume that the marginal productivity of increasing V is higher for people with poor initial health (low H PRE ). (Figure 2 ) As a rule, increases in the quantity and quality of medical care
are probably more valuable to people in poor initial health than they are to people in excellent initial health. We will present empirical evidence that provides strong support for this negative interaction.
Since people with low education and income are more likely to be in poor initial health than people with high education and income, pharmaceutical-embodied technical progress may be biased towards the less-educated. 7 If so, it tends to reduce inequality as it contributes to economic growth.
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These assumptions imply that (for given Y), equilibrium V is inversely related to H PRE : individuals in poor initial health will tend to use newer drugs than people in excellent initial health. This is why b 1 from equation (1) 
Then plim(b 1 ) = β 1 + β 3 β PRE.V , where β PRE.V is the slope coefficient from the simple "auxiliary" regression of H PRE on V. Since we hypothesize that β 3 > 0 and β PRE.V < 0,
Fortunately, we have data on H PRE as well as on H POST and V, so we can estimate eq. (5), i.e. we can control for pre-treatment health. In fact, we can extend and generalize the model as follows:
According to the "negative interaction" hypothesis discussed above, inclusion of the interaction term (V * H PRE ) is appropriate.
We have argued that controlling for initial health status affords a better representation of the health production function than one without. However, the health Further, using health utilization as a proxy for shocks and assuming a linear production function, we modify equation (6) to give:
Prescription refers to the number of prescriptions
Physician is the number of physician visits
Hospital is the number of inpatient admissions β 4 , β 5 , and β 6 are postulated to be negative
The model specified in equation (8) 
Data
In order to estimate eq. (6) • Difficulty lifting 10 pounds? (no difficulty, some difficulty, a lot of difficulty, unable to do) • Difficulty walking up 10 steps? (no difficulty, some difficulty, a lot of difficulty, unable to do, completely unable to walk) • Difficulty walking 3 blocks? (no difficulty, some difficulty, a lot of difficulty, unable to do) • Difficulty walking a mile? (no difficulty, some difficulty, a lot of difficulty, unable to do) • Difficulty standing 20 minutes? (no difficulty, some difficulty, a lot of difficulty, unable to do) • Difficulty bending/stooping? (no difficulty, some difficulty, a lot of difficulty, unable to do) • Difficulty reaching overhead? (no difficulty, some difficulty, a lot of difficulty, unable to do) • Difficulty using fingers to grasp? (no difficulty, some difficulty, a lot of difficulty, unable to do)
We recoded all of our health measures to take the value 0 for the worst health outcome ("zero health output") and the value 1 for the best health outcome ("maximum health output"). Using the perceived health status measure and a mortality indicator ( Figure 4 shows the number of new molecular entities approved per year, 13 The other health status variables available from the MEPS dataset do not permit us to compute 'reasonable' (composite) continuous health status. We employ this strategy exclusively for our 'mean level of difficulty' measure. See Wells (1996) for a discussion of the construction of health status variables using survey results. 14 During the interviews, the list of 7questions pertaining to detailed physical activities were asked only to respondents who indicated having limitations in physical functioning. We recoded all respondents with no physical limitation as having 'no difficulty' in the set of all detailed physical activities.
as computed from both lists. 15 We consider the first list to be more reliable for the 1950-1993 period, since the FDA constructed it for the specific purpose of identifying NMEs approved during the period. We use the second list only to provide data on NMEs approved during 1939-1949 and 1994-1997 . We matched Multum active ingredient names to ingredient names contained in FDA new molecular entity approvals.
Only 60 vintage. This would not affect the consistency of our estimates, provided that the rate of pharmaceutical-embodied technical progress was the same after 1939 as it was before 1939. It would, however, reduce the precision (efficiency) of our estimates, for two reasons. First, it would reduce the size of the sample by almost a third. Second, and probably more importantly, it would substantially reduce the range (and variance) of vintage. The greater this range, the greater the precision of the estimate of β 1 (= δH POST / δV).
17 15 We also merged the two lists, by new drug approval number, and calculated the difference in approval years recorded in the two lists. The mean and median differences were both approximately zero, and 98% of the differences were between -2 and +2 years, but there were 5 cases in which the absolute difference exceeded 10 years. 16 These figures treat a prescription for a combination drug-a drug with multiple ingredients-as a prescription for each ingredient. For example, a prescription for a drug containing the two ingredients benzalkonium chloride and tyloxapol is treated as two prescriptions, one for each ingredient. 17 If you seek to identify the effect of X on Y, you want X to vary a lot. To summarize, we will estimate five different versions of the model:
Covariates. All of the models we estimate include one prescription-level covariate-the diagnosis for which the drug was consumed-and the following person-level covariates:
18 Wald (1940) was apparently the first to propose using this kind of dummy variable as an instrument for a regressor subject to measurement error. Censoring of vintages may not be the only source of vintage measurement error. One reason is that there is probably considerable variation in the lag between the time of drug discovery and the time of FDA approval; the former may be a more appropriate measure of vintage, but is unobserved. A second is that some drugs ("standard review" drugs) may be very similar to previously approved ("priority review") drugs; perhaps the "effective vintage" of standard-review drugs is the vintage of the preceding priority-review drugs to which they are similar. Each observation contains the vintage of the drug 20 , the diagnosis for which the drug was prescribed, the pre-and post-treatment health status of the person cons uming the drug, and person-level covariates. Hence, the model is of the form:
+ diagnosis effects + u ij (7) where V ij denotes the jth prescription consumed by person i.
Estimation issues.
Due to the categorical nature of the H POST measures listed above, ideally one would estimate model (7) using an (ordered) probit or similar procedure.
Unfortunately, due to the large number of ("nuisance") parameters in the model (600+ diagnosis effects, 100 age effects, 20 education effects, etc.), the probit estimation procedure often failed to converge. Second, our unit of observation is at the prescription level, allowing individuals with more than one prescription event to have multiple entries.
We correct for the correlation across such observations by reporting estimates of eq. (7) 19 Hence, if person A had 10 prescriptions and person B had 5, person A would contribute twice as many observations to the sample. Unweighted estimation at the prescription level is similar to weighted estimation at the person level, where the weight is the person's number of prescriptions. Since diagnosis can vary across prescriptions for a given individual, it is easier to control for diagnosis at the prescription level than it is at the person level. 20 In principle, it would be desirable to decompose approvals not only according to active ingredients, but to different combinations and dosages as well, as these may affect the efficacy of drugs to some degree. However, this is difficult to implement in practice. Moreover, FDA data indicate that new ingredients are more likely to be significant innovations than new formulations or combinations of existing ingredients. Our data reveal that 42% of the new molecular entities (NMEs ) approved during 1990-2001 were "priorityreview approvals" i.e. considered by the FDA to represent "significant improvement compared to marketed products, in the treatment, diagnosis, or prevention of a disease". On the other hand, only 14% of non-NME NDAs (including new formulations or combinations) approved were priority-review approvals.
using a random effects model that accounts for clustered standard errors 21 . For binary dependent variables, this is known as the "linear probability model," which has certain limitations. We hope to supersede these limitations in the future.
Suppose that H POST,i equals 1 if person i has no limitation in physical functioning post-treatment, and otherwise equals zero. Within the linear probability model framework, β 1 is the (short-run) effect of a one-year increase in vintage on the probability of no limitation in physical functioning. 22 An estimate of β 1 allows us to calculate both
(1) the increase in drug cost necessary to achieve a given improvement in post-treatment health, and (2) the rate of pharmaceutical-embodied technical progress.
Let P rx represent the price of a prescription. Then dP rx / dV is the derivative of prescription price with respect to vintage-the slope of the vintage-price profile. β 1 = dH POST / dV is the derivative of post-treatment health with respect to vintage-the slope of the vintage-health profile. Hence (dP rx / dV) / β 1 = dP rx / dH POST is the cost of the increase in vintage necessary to achieve a given improvement in post-treatment health.
For example, if dP rx / dV = $1.50 (prescription cost increases at the rate of $1.50 per year of vintage) and β 1 = .00018, then dP rx / dH POST = $1.50 / .00018 = $8433. The increase in vintage required to achieve a .01 increase in the probability of no limitation in physical functioning would increase prescription cost by $84.33.
23
The percentage change in the probability of no limitation from a one-year increase in vintage is β 1 / mean (H POST ). For example, if β 1 = .00018 and mean (H POST ) = .671, the percentage change in probability from a one-year increase in vintage is .00018 / 21 In addition, we attempted the alternative of weighting each observation by the inverse of the number of prescriptions received by that individual -the estimates generally showed a lower standard error, and remained significant. 22 Assuming for simplicity that there is no interaction effect (i.e. that β 4 = 0). The long-run effect is -β 1 / (1-β 3 ). 23 This approach can also be used to estimate the cost of the increase in vintage necessary to achieve a oneyear increase in life exp ectancy. Suppose that H POST is equal to 1 if the person was alive at the date of the second interview, and equal to zero if the person had died. Then β 1 is the effect of vintage on the probability of survival. Let LE(t) represent a person's remaining life expectancy at year t, and S(t,t+1) represent the probability of survival from age t to age t+1. Then LE(t) ≈ S(t, t+1 (In a steady state, the mean vintage of drugs would increase at the rate of one year per year.) The National Institute of Aging-sponsored study cited above found that "the number of older people who become severely disabled has been declining gradually for more than a decade, but the decline became much sharper at the end of the 1990's."
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As Figure 4 indicates, there was a large increase in the mid-1990s in the number of new drugs approved. This increase, which was primarily due to enactment of the Prescription Drug User Fee Act, may help to explain the acceleration in the decline in disability at the end of the 1990s.
Descriptive statistics. Summary statistics are presented in Table 2 . These are presented at both the person level and the prescription level. The prescription-level statistics can be thought of as weighted person-level statistics, where the weight is the person's number of prescriptions. People in poor health tend to consume more prescriptions than people in 24 This ignores the value of the time people devote to their own health care. As Folland et al (2001, p. 121) note, "The consumer does not merely purchase health passively from the market. Instead, the consumer produces it, spending time on health-improving efforts in addition to purchasing medical inputs." Accounting for the value of time would reduce the ratio of the cost of the prescription to total health care cost, and increase the estimated rate of pharmaceutical-embodied technical progress. 25 The estimated rate of pharmaceutical-embodied technical progress is invariant with respect to the scale, . We code all of our H POST measures to take the value 0 for the worst health outcome ("zero health output") and the value 1 for the best health outcome ("maximum health output"). Estimates reported in the fourth column are also based on the full sample of prescriptions and a continuous vintage measure; in this column the vintage of prescriptions of unknown (pre-1939) vintage is assumed to be 1920, rather than 1900. In general, this increases the point estimates of the vintage coefficients: the rate of health improvement with respect to vintage appears to be larger, since the old drugs are assumed to be less old. But the coefficients don't change by an enormous amount, and they remain highly significant, suggesting that our results won't be too sensitive to the choice of imputed value for missing vintages. 28 Since the t-statistics in column 3 are generally larger than those in column 4, henceforth we will impute 1900 to missing vintages. 28 Since the Rx-price coefficient is also higher in column 4 than it is in column 3, estimates of dP rx / dH POST = (dP rx / dV) / β 1 from the two columns will be quite similar.
The fifth and last column of The estimates reported in Table 3 do not control for pre-treatment health status.
In Table 4 we report estimated effects of vintage on health that do control for pretreatment health status, i.e. we report estimates from the "dynamic" equation H POST,i = β 0 + β 1 V ij + β 2 Z i + β 3 H PRE ,i + diagnosis effects + u ij . Column 2 of Table 4 reports estimates of the short-run effect of vintage on health, β 1 , and column 3 reports estimates of the long-run effect, (β 1 / (1 -β 3 )). For purposes of comparison, we also report in column 1 estimates of β 1 from the "static" model (excluding pre-treatment health); these estimates are also reported in column 5 of Table 3 . We also report, for each estimate, the cost of the increase in vintage required to achieve a unit increase in post-treatment health The short-run estimate from the dynamic model is higher ($5114), but the long-run effect is lower ($2273). The fact that the long-run estimate is lower than the static estimate is consistent with the view that people in poor initial health tend to consume newer drugs, so that failure to control for initial health biases the estimates of the effect of vintage on health towards zero, and estimates of the cost of the increase in vintage required to achieve better health away from zero. The rate of embodied technical progress implied by the long-run effect is quite high: 9.3%.
The QUALITY OF LIFE index, estimates of which are presented next in Table 4 But in addition to this broad (binary) indicator of physical limitations, MEPS provides data on respondents' ability to perform seven specific physical activities (lifting 10 pounds, walking 3 blocks, etc.). 30 As mentioned earlier, we use this information to compute a composite measure called MEAN LEVEL OF DIFFICULTY. As shown in Table 4 , people who consume newer drugs tend to have lower levels of mean difficulty.
The long-run estimate indicates that the cost of preventing physical difficulty is $2479, and the annual rate of technical progress with respect to physical difficulty is 4.8% 31 .
The estimates we have presented so far measure, we believe, the average effect of drug vintage on health. In our theoretical discussion we postulated that in reality, this effect may be heterogeneous: the effect of drug vintage on health is greater for people in initially poor health. To test this hypothesis, we estimated eq. (7), which includes both main and interaction vintage and pre-treatment health effects: H POST,i = β 0 + β 1 V ij + β 2 Z i 30 These variables indicate the degree, as well as the absence or presence, of physical limitation. 31 In fact, we also estimated models of respondents' ability to perform each of the seven activities separately (not reported). Almost all of the detailed physical activities variables strongly support the existence of pharmaceutical-embodied technical progress. People consuming newer drugs tend to experience greater increases (or smaller declines) in physical ability than peop le consuming older drugs. The average rate of embodied technical progress across all seven activities is about 4%. Since detailed physical limitation indicators (and their mean) provide evidence of embodied technical change while a crude measure does not, it is quite possible that if detailed cognitive limitation indicators were available, they (and their mean) would have provided evidence of embodied technical change. In the theoretical section, we postulated that a way to capture the impact of interim health shocks is to include health utilization. In light of this, we ran regressions using equation (8). Table 6 presents our results. For ease of comparison, we transfer the results obtained from the model without health utilization (namely column 2 of Table 4) to the first column of Table 6 . The second column lists estimates for the regressions that include utilization measures, namely number of prescriptions (prescription), number of physician visits (physician), and number of inpatient discharges (hospital). The final three columns of Table 6 display the coefficient estimate, standard error, t-statistic and p-value for each of these three utilization measures in corresponding regressions.
Focusing on the first two columns of Table 6 , it is immediately apparent that as hypothesized, the drug vintage coefficient has become less significant across all cases, Turning our attention next to the coefficients of the utilization variables, we notice that they are negative and highly significant in most instances 33 . This validates our conjecture that health utilization variables capture health shocks and consequently shocks affecting 'interim' health status. Another interesting observation is that the number of prescription drugs is by far the most significant among all three health utilization
measures. An exception to this norm lies in the regression on ALIVE, where not surprisingly, the number of inpatient discharges (hospital) emerges as the most significant utilization variable affecting post-treatment health status. Finally, in regressions that account for both the interaction term (recall Table 5 ) as well as health utilization, we obtain results qualitatively similar to those in Table 5 , strengthening our claim that people in poor initial health tend to benefit most from pharmaceutical-embodied technical change 34 .
Overall, the evidence suggests that the people in poor initial health tend to benefit most from pharmaceutical-embodied technical change. As the following table shows, the 33 In the specification shown in Table 6 , we employ the logarithm of the utilization variables in order to highlight the negative relationship between them and each dependent (health status) variable. Our estimates remain robust to alternative specifications of these utilization variables, including one in which they were introduced as class variables, as well as a linear specification. 34 We do not present these results as they are also quantitatively close to those reported in Table 5 .
health of people with low levels of education (hence low skills and income) tends to be worse than the health of people with more education. Hence pharmaceutical-embodied technical change may have a tendency to reduce inequality as well as promote economic growth, broadly defined.
Summary and conclusions
For sustained economic growth to occur, technological progress is necessary.
There are two kinds of technical progress-disembodied and embodied-and both kinds are driven by research and development. A number of econometric studies have concluded that technical progress embodied in equipment is a major source of manufacturing productivity growth.
Other recent research has suggested that, over the long run, growth in the U.S.
economy's "health output" has been at least as large as the growth in non-health goods and services. Moreover, one important input in the production of healthpharmaceuticals-is even more R&D-intensive than equipment.
In this paper we have tested the pharmaceutical-embodied technical progress hypothesis-the hypothesis that newer drugs increase the length and quality of life-and estimated the rate of progress. To do this, we estimated health production functions, in which the dependent variables are various indicators of post-treatment health status (such as survival, perceived health status, and presence of physical or cognitive limitations), 35 The reported differences in rates are adjusted for age, sex, race, marital status, and insurance coverage.
and the regressors include drug vintage (the year in which the FDA first approved a drug's active ingredient(s)) and indicators of pre-treatment health status. We estimated these relationships using extremely disaggregated-prescription-level-cross-sectional data derived primarily from the 1997 Medical Expenditure Panel Survey.
We found that people who used newer drugs had better post-treatment health than people using older drugs for the same condition, controlling for pre-treatment health, age, sex, race, marital status, education, income, and insurance coverage.
• Survival. People consuming newer drugs during the period were more likely to be alive at the end of the period, whether or not we control for perceived health status at the beginning of the period. The estimates imply that the cost of the increase in vintage required to keep the person alive is $8214. This cost seems quite low, in comparison with other researchers' estimates of the economic value of a life-year: our estimate of the cost of preventing a death is lower than Murphy and Topel's estimate of the value of remaining alive for one month.
• Perceived health status. Vintage has a positive and highly significant effect on perceived health status and a quality of life index whether or not we control for perceived health status at the beginning of the period. The rate of embodied technical progress implied by the long-run effect is quite high: 9.3%.
• Activity or social limitations. People were less likely to experience activity or social limitations if they had consumed newer drugs, conditiona l on their previous limitations (and the other covariates). The long-run estimate indicates that the cost of preventing an activity limitation is $1745, and the annual rate of technical progress with respect to activity limitations is 8.4%.
• Physical limitations. Almost all of the seven detailed physical functioning variables (lifting 10 pounds, walking 3 blocks, etc.) reflect the existence of pharmaceutical-embodied technical progress. People consuming newer drugs tend to experience greater increases (or smaller declines) in physical ability than people consuming older drugs. The average rate of embodied technical progress across all seven activities is about 4%.
In addition, we test an alternative model which accounts for health shocks experienced during the period (between pre-and post-treatment health status), by using health utilization measures such as the number of prescriptions, physician visits, and inpatient discharges, as indicators of these shocks. As postulated, we find these utilization variables are negatively related to post-treatment health status. While the drug vintage estimates from this new specification are smaller and less significant than in the model without health utilization, our qualitative results are unchanged. We argue that this does not necessarily imply that impact of drug vintage is less -adjusting for utilization simply decomposes the drug vintage coefficient into its direct and indirect (via utilization variables) effects.
Last, most of the health measures indicate that the effect of drug vintage on health is positive and significant for people with low initial health and insignificant for people with high initial health, and that the difference between these effects is statistically significant. This suggests that the people in poor initial health tend to benefit most from pharmaceutical-embodied technical change. The health of people with low levels of education (hence low skills and income) tends to be worse than the health of people with more education. Hence, in contrast to equipment-embodied technical progress, which tends to increase economic inequality, pharmaceutical-embodied technical progress has a tendency to reduce inequality as well as promote economic growth, broadly defined. Estimates of drug vintage coefficients from models excluding and including controls for health utilization 
